作者
Chandrika Gowda, Mansi Sachdev, Sunil Muthusami, Malika Kapadia, Lidija Petrovic-Dovat, Melanie Hartman, Yali Ding, Chunhua Song, Jonathon L Payne, Bi-Hua Tan, Sinisa Dovat
发表日期
2017/1/1
来源
Current Pharmaceutical Design
卷号
23
期号
1
页码范围
95-107
出版商
Bentham Science Publishers
简介
Background
Casein kinase II (CK2) is a pro-oncogenic protein, which is emerging as a promising therapeutic target in cancer. Recent studies have revealed an important role for CK2 in tumorigenesis. High levels of CK2 are noted in many malignancies including leukemia. Use of CK2 inhibitors in various malignancies including breast, prostate, and lung cancer are being tested. Although many CK2 inhibitors exist, only a few have emerged as selective inhibitors that are potent and effective. CX-4945 is a selective, orallybioavailable small molecule inhibitor, which has shown encouraging results in pre-clinical models of leukemia.
Methods
In this review we will elaborate on the structure and physiological function of the CK2 protein as well as its role in cancer. We will review, in depth, the role of CK2 in leukemia and its mechanisms of tumorigenesis via phosphorylation of the tumor suppressor protein Ikaros. We will …
引用总数
20172018201920202021202220232024756816393
学术搜索中的文章
C Gowda, M Sachdev, S Muthusami, M Kapadia… - Current Pharmaceutical Design, 2017